Cancer Family
Breast Neoplasm
CI-CAN-00000007Explore in graph →
Non-malignant2,895 active trials43 approved drugs310 evidence items
- NCIt
- C2910
- OncoTree
- BNNOS
- MeSH
- D000069584
- MeSH
- D001943
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000007Explore in graph →
Clinical trials
13,871 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT00129922 | Fluorouracil, Epirubicin, and Cyclophosphamide Alone or Followed by Paclitaxel for Early Breast Cancer | completed | Phase 3 | 1,289 | Spanish Breast Cancer Research GroupOTHER | 1 | Mar 6, 2023 | clinicaltrials |
| NCT00493870 | TAC Versus TC for Adjuvant Breast Cancer | completed | Phase 3 | 1,961 | US Oncology ResearchINDUSTRY | 1 | Mar 2, 2023 | clinicaltrials |
| NCT00301457 |
| Different Durations of Adjuvant Anastrozole Therapy After 2 to 3 Years Tamoxifen Therapy in Breast Cancer(DATA) |
| completed |
| Phase 3 |
| 1,914 |
| Maastricht University Medical CenterOTHER |
| 1 |
| Feb 21, 2023 |
| clinicaltrials |
| NCT00281658 | Study In Women And Men With Metastatic Breast Cancer That Have Overexpression Of ErbB2 | completed | Phase 3 | 444 | Novartis PharmaceuticalsINDUSTRY | 8 | Feb 10, 2023 | clinicaltrials |
| NCT03433313 | Efficacy and Safety Study of EG12014 Compared With Herceptin in Subjects With HER2 Positive Early Breast Cancer | completed | Phase 3 | 807 | EirGenix, Inc.INDUSTRY | 11 | Jan 20, 2023 | clinicaltrials |
| NCT03462251 | Ribociclib and Endocrine Therapy or Chemotherapy With or Without Bevacizumab for Metastatic Breast Cancer in First Line(RIBBIT) | completed | Phase 3 | 41 | iOMEDICO AGINDUSTRY | 1 | Jan 19, 2023 | clinicaltrials |
| NCT03294330 | SPY-X: A Study to Assess the Feasibility of Using SPY Alone for Sentinel Node Localization for Melanoma or Breast Cancer(SPYX) | completed | Phase 3 | 35 | Milton S. Hershey Medical CenterOTHER | 1 | Jan 12, 2023 | clinicaltrials |
| NCT01598298 | S1202: Duloxetine Hydrochloride for Muscle/Joint Pain in Early-Stage Breast Cancer Receiving Hormone Therapy | completed | Phase 3 | 299 | SWOG Cancer Research NetworkNETWORK | 1 | Dec 16, 2022 | clinicaltrials |
| NCT00433589 | Genetic Testing or Clinical Assessment in Determining the Need for Chemotherapy in Women With Breast Cancer That Involves No More Than 3 Lymph Nodes(MINDACT) | completed | Phase 3 | 6,600 | European Organisation for Research and Treatment of Cancer - EORTCNETWORK | 1 | Nov 17, 2022 | clinicaltrials |
| NCT04874935 | The Possible Efficacy and Safety of Lansoprazole Co-administration With Neoadjuvant Chemotherapy in Women With Breast Cancer | completed | Phase 3 | 66 | Tanta UniversityOTHER | 1 | Nov 15, 2022 | clinicaltrials |
| NCT01403779 | Comparison of the Cosmetic Outcome of Hypofractionated Versus Normofractionated IMRT in Treatment of Breast Cancer(KOSIMA) | completed | Phase 3 | 226 | Universitätsmedizin MannheimOTHER | 1 | Nov 7, 2022 | clinicaltrials |
| NCT04109391 | Extension Study to Provide Adjuvant Treatment Following Neoadjuvant Treatment and Surgical Resection in Protocol TX05-03 | completed | Phase 3 | 338 | Tanvex BioPharma USA, Inc.INDUSTRY | 10 | Oct 26, 2022 | clinicaltrials |
| NCT00377156 | Stereotactic Radiation Therapy With or Without Whole-Brain Radiation Therapy in Treating Patients With Brain Metastases | completed | Phase 3 | 213 | Alliance for Clinical Trials in OncologyOTHER | 2 | Sep 16, 2022 | clinicaltrials |
| NCT03705429 | A Study Comparing Two Standard of Care Adjuvant Chemotherapy Regimens for Lower Risk HER-2 Positive Breast Cancer | completed | Phase 3 | 51 | London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph'sOTHER | 1 | Aug 19, 2022 | clinicaltrials |
| NCT00087178 | Comparison of Two Combination Chemotherapy Regimens in Treating Women With Breast Cancer | completed | Phase 3 | 2,722 | NSABP Foundation IncNETWORK | 3 | Aug 11, 2022 | clinicaltrials |
| NCT02594371 | Ph3 Study To Determine Safety,Tolerability&Tumor Response Of Oraxol Compared To Taxol In Metastatic Breast Cancer | completed | Phase 3 | 402 | Athenex, Inc.INDUSTRY | 10 | Aug 3, 2022 | clinicaltrials |
| NCT02425891 | A Study of Atezolizumab in Combination With Nab-Paclitaxel Compared With Placebo With Nab-Paclitaxel for Participants With Previously Untreated Metastatic Triple-Negative Breast Cancer (IMpassion130) | completed | Phase 3 | 902 | Hoffmann-La RocheINDUSTRY | 40 | Jul 19, 2022 | clinicaltrials |
| NCT00039780 | Evaluation of BNP7787 for the Prevention of Neurotoxicity in Metastatic Breast Cancer Patients Receiving Weekly Paclitaxel | completed | Phase 3 | 764 | BioNumerik Pharmaceuticals, Inc.INDUSTRY | 0 | Jul 13, 2022 | clinicaltrials |
| NCT02574455 | Trial of Sacituzumab Govitecan in Participants With Refractory/Relapsed Metastatic Triple-Negative Breast Cancer (TNBC)(ASCENT) | completed | Phase 3 | 529 | Gilead SciencesINDUSTRY | 7 | Jun 15, 2022 | clinicaltrials |
| NCT00003857 | Radiation Therapy With or Without Optional Tamoxifen in Treating Women With Ductal Carcinoma in Situ | completed | Phase 3 | 636 | Radiation Therapy Oncology GroupNETWORK | 2 | May 25, 2022 | clinicaltrials |
| NCT01517802 | A Study That Provides Long-term Safety Follow-up and Examines Long-term Exposure to Abiraterone Acetate | completed | Phase 3 | 32 | Janssen Research & Development, LLCINDUSTRY | 7 | May 10, 2022 | clinicaltrials |
| NCT01095003 | Trial of Vinflunine Plus Capecitabine in Advanced Breast Cancer | completed | Phase 3 | 770 | Pierre Fabre MedicamentINDUSTRY | 21 | Apr 28, 2022 | clinicaltrials |
| NCT02546934 | ABX Plus Cisplatin Versus Gemcitabine Plus Cisplatin in Triple Negative Breast Cancer (TNBC)(TNBC) | completed | Phase 3 | 254 | Fudan UniversityOTHER | 1 | Apr 22, 2022 | clinicaltrials |
| NCT00887536 | A Clinical Trial Comparing the Combination of TC Plus Bevacizumab to TC Alone and to TAC for Women With Node-Positive or High-Risk Node-Negative, HER2-Negative Breast Cancer | completed | Phase 3 | 1,613 | NSABP Foundation IncNETWORK | 2 | Apr 20, 2022 | clinicaltrials |
| NCT02336750 | Adding Mirtazapine to Dexamethasone and Aprepitant for Delayed Emesis | completed | Phase 3 | 212 | Fudan UniversityOTHER | 1 | Apr 20, 2022 | clinicaltrials |
| NCT01702571 | A Study of Trastuzumab Emtansine in Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Breast Cancer Who Have Received Prior Anti-HER2 And Chemotherapy-based Treatment | completed | Phase 3 | 2,185 | Hoffmann-La RocheINDUSTRY | 43 | Apr 4, 2022 | clinicaltrials |
| NCT03764943 | Immunonutrition and Carbohydrate Loading Strategies in Breast Reconstruction | completed | Phase 3 | 125 | University of Wisconsin, MadisonOTHER | 1 | Mar 29, 2022 | clinicaltrials |
| NCT02643420 | SPI-2012 vs Pegfilgrastim in the Management of Neutropenia in Participants With Breast Cancer With Docetaxel and Cyclophosphamide (ADVANCE)(ADVANCE) | completed | Phase 3 | 406 | Spectrum Pharmaceuticals, IncINDUSTRY | 3 | Mar 2, 2022 | clinicaltrials |
| NCT02953340 | SPI-2012 vs Pegfilgrastim in Management of Neutropenia in Breast Cancer Participants With Docetaxel and Cyclophosphamide | completed | Phase 3 | 237 | Spectrum Pharmaceuticals, IncINDUSTRY | 6 | Mar 2, 2022 | clinicaltrials |
| NCT02467868 | Efficacy and Safety Study With MYL-1401H and Neulasta | completed | Phase 3 | 193 | Mylan Inc.INDUSTRY | 6 | Feb 14, 2022 | clinicaltrials |
| NCT02472964 | Study of Efficacy and Safety of Myl1401O + Taxane vs Herceptin©+ Taxane for 1st Line, Met. Br. Ca.(HERiTAge) | completed | Phase 3 | 500 | Mylan Inc.INDUSTRY | 15 | Feb 14, 2022 | clinicaltrials |
| NCT00408863 | Livial Intervention Following Breast Cancer; Efficacy, Recurrence and Tolerability Endpoints (LIBERATE)(COMPLETED)(P05885) | completed | Phase 3 | 3,148 | Organon and CoINDUSTRY | 0 | Feb 4, 2022 | clinicaltrials |
| NCT04951245 | Ultrasound-assisted CNSs Mapping Versus Dual-tracer-guided Sentinel Lymph Node Biopsy(UltraCars) | completed | Phase 3 | 330 | Guangdong Provincial People's HospitalOTHER | 1 | Jan 28, 2022 | clinicaltrials |
| NCT01945775 | A Study Evaluating Talazoparib (BMN 673), a PARP Inhibitor, in Advanced and/or Metastatic Breast Cancer Patients With BRCA Mutation (EMBRACA Study)(EMBRACA) | completed | Phase 3 | 431 | PfizerINDUSTRY | 16 | Jan 20, 2022 | clinicaltrials |
| NCT02600923 | Palbociclib Plus Letrozole For Postmenopausal Women With HR(+) HER2(-) Advanced Breast Cancer For Whom Letrozole Is Deemed Appropriate | completed | Phase 3 | 131 | PfizerINDUSTRY | 4 | Jan 20, 2022 | clinicaltrials |
| NCT03556358 | Trial to Compare the Safety, Efficacy and Immunogenicity of TX05 With Herceptin® in HER2+ Early Breast Cancer | completed | Phase 3 | 809 | Tanvex BioPharma USA, Inc.INDUSTRY | 10 | Jan 14, 2022 | clinicaltrials |
| NCT02482753 | Trial of Chidamide in Combination With Exemestane in Patients With Advanced Breast Cancer | completed | Phase 3 | 365 | Chipscreen Biosciences, Ltd.INDUSTRY | 1 | Jan 12, 2022 | clinicaltrials |
| NCT02896855 | A Study to Evaluate the Efficacy and Safety of Pertuzumab + Trastuzumab + Docetaxel Versus Placebo + Trastuzumab + Docetaxel in Previously Untreated Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Metastatic Breast Cancer(PUFFIN) | completed | Phase 3 | 243 | Hoffmann-La RocheINDUSTRY | 1 | Dec 16, 2021 | clinicaltrials |
| NCT02555657 | Study of Single Agent Pembrolizumab (MK-3475) Versus Single Agent Chemotherapy for Metastatic Triple Negative Breast Cancer (MK-3475-119/KEYNOTE-119) | completed | Phase 3 | 622 | Merck Sharp & Dohme LLCINDUSTRY | 0 | Dec 10, 2021 | clinicaltrials |
| NCT00703326 | Phase III Study of Docetaxel + Ramucirumab or Placebo in Breast Cancer | completed | Phase 3 | 1,144 | Eli Lilly and CompanyINDUSTRY | 23 | Dec 6, 2021 | clinicaltrials |
| NCT02468739 | Effect of GM1 in Prevention of Taxanes Induced Neurotoxicity in Operable Breast Cancer | completed | Phase 3 | 206 | Sun Yat-sen UniversityOTHER | 1 | Nov 4, 2021 | clinicaltrials |
| NCT03096847 | Study for Women and Men With Hormone-receptor Positive Locally Advanced or Metastatic Breast Cancer | completed | Phase 3 | 502 | Novartis PharmaceuticalsINDUSTRY | 1 | Oct 11, 2021 | clinicaltrials |
| NCT00078832 | Anastrozole in Preventing Breast Cancer in Postmenopausal Women at Increased Risk of Breast Cancer(IBIS II) | completed | Phase 3 | 3,864 | Queen Mary University of LondonOTHER | 14 | Oct 6, 2021 | clinicaltrials |
| NCT00553358 | Neo ALTTO (Neoadjuvant Lapatinib and/or Trastuzumab Treatment Optimisation) Study(Neo ALTTO) | completed | Phase 3 | 455 | Novartis PharmaceuticalsINDUSTRY | 24 | Sep 21, 2021 | clinicaltrials |
| NCT04059809 | Photobiomodulation for Breast Cancer Radiodermatitis | completed | Phase 2 / Phase 3 | 48 | AC Camargo Cancer CenterOTHER | 1 | Aug 13, 2021 | clinicaltrials |
| NCT03079219 | Olanzapine for the Prevention of Chemotherapy-Induced Nausea and Vomiting in Chinese Breast Cancer Patients | completed | Phase 3 | 120 | CCTUOTHER | 1 | Jul 28, 2021 | clinicaltrials |
| NCT00127205 | S0307 Phase III Trial of Bisphosphonates as Adjuvant Therapy for Primary Breast Cancer. | completed | Phase 3 | 6,097 | SWOG Cancer Research NetworkNETWORK | 0 | Jul 2, 2021 | clinicaltrials |
| NCT04075058 | Hypofractionated Radiation Therapy in Patients With Breast Cancer(HRBC) | completed | Phase 3 | 1,070 | Post Graduate Institute of Medical Education and Research, ChandigarhOTHER | 1 | Jun 23, 2021 | clinicaltrials |
Data updated 23 days agoSource updated Mar 6, 2023source: clinicaltrials